[1] Singal AK, Mathurin P. Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review[J]. JAMA, 2021,326(2):165-176.
[2] Huang DQ, Mathurin P, Cortez-Pinto H, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors[J]. Nat Rev Gastroenterol Hepatol,2023,20(1):37-49.
[3] Wu X, Fan X, Miyata T, et al. Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease[J]. Annu Rev Pathol,2023,18:411-438.
[4] You M, Arteel GE. Effect of ethanol on lipid metabolism[J]. J Hepatol,2019,70(2):237-248.
[5] Luo P, Zheng M, Zhang R, et al.S-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling[J]. Acta Pharm Sin B,2021,11(3):668-679.
[6] Clugston RD, Yuen JJ, Hu Y,et al. CD36-deficient mice are resistant to alcohol-and high-carbohydrate-induced hepatic steatosis[J]. J Lipid Res,2014,55(2):239-246.
[7] Thoudam T, Chanda D, Lee JY, et al. Enhanced Ca2+-channeling complex formation at the ER-mitochondria interface underlies the pathogenesis of alcohol-associated liver disease[J]. Nat Commun, 2023,14(1):1703.
[8] Hyun J, Al Abo M, Dutta RK, et al. Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease[J]. J Hepatol,2021,75(3):623-633.
[9] López-Cánovas JL, Hermán-Sánchez N, Del Rio-Moreno M, et al. PRPF8 increases the aggressiveness of hepatocellular carcinoma by regulating FAK/AKT pathway via fibronectin 1 splicing[J]. Exp Mol Med,2023, 55(1):132-142.
[10] Yang Z, Han S, Zhang T,et al. Transcriptomic Analysis Reveals the Messenger RNAs Responsible for the Progression of Alcoholic Cirrhosis[J]. Hepatol Commun,2022,6(6):1361-1372.
[11] Hyun J, Sun Z, Ahmadi AR, et al. Epithelial splicing regulatory protein 2-mediated alternative splicing reprograms hepatocytes in severe alcoholic hepatitis[J]. J Clin Invest,2020,130(4):2129-2145.
[12] Tufail M, Wu C. SRPKs: a promising therapeutic target in cancer[J]. Clin Exp Med,2023, 23(7):3093-3112.
[13] Nikolakaki E, Sigala I, Giannakouros T. Good Cop, Bad Cop: The Different Roles of SRPKs[J]. Front Genet,2022,13:902718.
[14] Pihlajamäki J, Lerin C, Itkonen P,et al. Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis[J]. Cell Metab,2011,14(2):208-218.
[15] Chen H, Shen F, Sherban A, et al. DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease[J]. Hepatology,2018,68(2):496-514.
[16] Li G, Chen H, Shen F, et al. Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis[J]. Hepatology,2023, 78(5):1506-1524.
[17] Chao X, Wang S, Ma X, et al. Persistent mTORC1 activation due to loss of liver tuberous sclerosis complex 1 promotes liver injury in alcoholic hepatitis[J]. Hepatology,2023,78(2):503-517. |
